?Ruxolitinib | USP/EP-Certified JAK1/JAK2 Inhibitor | Bulk API for Myelofibrosis & GVHD?

?? ?Product Overview?

Ruxolitinib (CAS 941678-49-5) is a potent oral inhibitor targeting Janus kinase 1/2 (JAK1/JAK2), approved for treating myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease (GVHD). It modulates the JAK-STAT signaling pathway to reduce inflammation and abnormal cell proliferation.

?? ?Key Advantages?

• ?High Purity?: ≥98% HPLC purity compliant with ?USP/EP? standards.

• ?Bulk Flexibility?: Available in 1g to 100kg batches with batch-specific COA, MSDS, and stability testing.

• ?Soluble Formulation?: White crystalline powder soluble in DMSO (28 mg/ml) and ethanol (15 mg/ml with warming).

?? ?Applications?

1. ?Myelofibrosis Therapy?: Reduces spleen size and alleviates symptoms in primary/secondary myelofibrosis.

2. ?GVHD Management?: Effective for steroid-resistant acute GVHD.

3. ?Research?: Key reference standard for studying JAK-STAT signaling in oncology and immunology.

?? ?Quality Compliance?

• Certified under ?USP/EP? guidelines with heavy metals <20ppm, residual solvents <10ppm, and microbial limits per ICH Q3D.

• Stability tested for 24 months at recommended storage conditions (-20°C).

?? ?Market Trends?

The global myelofibrosis treatment market is projected to grow at ?7.5% CAGR (2025-2030)?, driven by demand for targeted therapies like Ruxolitinib. Its dual JAK1/JAK2 inhibition positions it as a cornerstone in hematology and oncology pipelines.